2CE MECP2 (101040128)

  https://cordis.europa.eu/project/id/101040128

  Horizon Europe (2021-2027)

  Visualising neuronal signalling dynamics within intact neuronal circuits: Deciphering the role of cell-specific MeCP2 dynamics in neuronal function and dysfunction

  ERC STARTING GRANTS (ERC-2021-STG)

  biosensors  ·  gene therapy  ·  fluorescence lifetime imaging  ·  mutation  ·  pathology

  2022-10-01 Start Date (YY-MM-DD)

  2027-09-30 End Date (YY-MM-DD)

  € 1,500,000

  Description

Epigenetic signalling pathways are required to translate external sensory input to neuronal gene modulation and function, and disruption of epigenetic signals leads to devastating brain pathologies. One prominent example is Rett syndrome (RTT), a postnatal neurodevelopmental disease which results in rapid deterioration of sensory, motor, cognitive, and social functions. RTT is caused by loss of function mutations in a single gene encoding for Methyl-CpG binding protein 2 (MeCP2), an abundant and multifunctional methylation reader in the brain. While transgenic mouse models of MeCP2 loss have provided significant insights into RTT, they also revealed the vast complexity of the regulation of MeCP2 signalling and cell- specific heterogeneity. Importantly both a deficit and a surplus of MeCP2 give rise to pathological phenotypes. Here, we will develop an imaging-based approach to monitor endogenous MeCP2 signalling and dynamics in intact neuronal circuits in awake behaving mice. We will combine CRISPR/Cas9 genome editing to fluorescently label endogenous MeCP2 with FRET based biosensors to detect dynamic MeCP2 signalling without perturbing its innate regulation. In vivo two-photon fluorescence lifetime imaging will enable dual imaging of MeCP2 signalling and concurrent neuronal activity. Using this approach, we will map the functional landscape of MeCP2 activity in the intact mouse brain across cell-type, circuit, and sensory experience. We will also image in vivo MeCP2 signalling in transgenic mice with common RTT mutations. This will allow us to detect early cell-type specific MeCP2 dysfunction and avoid broad late-stage RTT symptoms. The direct visualisation of the intricate interplay between MeCP2 signalling and neuronal function within intact neuronal circuits will be transformative since it will shed light on the physiological role of epigenetic signalling in the brain and provide vital insights to future therapeutic interventions.

  Complicit Organisations

1 Israeli organisation participates in 2CE MECP2.